Application of pharmacoepidemiological approaches to generate real-world evidence on the use and impact of metastatic colorectal cancer medicines
HMA Yasin - 2023 - stax.strath.ac.uk
Introduction: Metastatic colorectal cancer (mCRC) is characterised by multiple treatment
strategies. Randomised clinical trials are not always aligned with clinical practice, and …
strategies. Randomised clinical trials are not always aligned with clinical practice, and …
Comparative effectiveness and safety of first-line systemic anti-cancer treatments of metastatic colorectal cancer: A systematic review and meta-analysis.
Background: Metastatic colorectal cancer (mCRC) is characterised by multiple treatment
strategies. Randomised clinical trials are not always aligned with the clinical practice, and …
strategies. Randomised clinical trials are not always aligned with the clinical practice, and …
[HTML][HTML] Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A …
KKH Goey, R Mahmoud, H Sørbye, B Glimelius… - European Journal of …, 2018 - Elsevier
Background Patient characteristics and stratification factors are important factors influencing
trial outcomes. Uniform reporting on these parameters would facilitate cross-study …
trial outcomes. Uniform reporting on these parameters would facilitate cross-study …
Overall survival in phase 3 clinical trials and the Surveillance, Epidemiology, and End Results database in patients with metastatic colorectal cancer, 1986-2016: a …
C Shen, D Tannenbaum, R Horn, J Rogers… - JAMA network …, 2022 - jamanetwork.com
Importance Phase 3 trials for patients with metastatic colorectal cancer (mCRC) have been
conducted with varying designs and often with surrogate end points for overall survival (OS) …
conducted with varying designs and often with surrogate end points for overall survival (OS) …
[HTML][HTML] Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: supported by the ARCAD Group
KKH Goey, H Sørbye, B Glimelius, RA Adams… - European Journal of …, 2018 - Elsevier
Background Patient characteristics and stratification factors are key features influencing trial
outcomes. However, there is substantial heterogeneity in reporting of patient characteristics …
outcomes. However, there is substantial heterogeneity in reporting of patient characteristics …
Balancing Risk and Benefit for First-Line Treatment of Metastatic Colorectal Cancer: A Graphic Communication Tool for Patients and Physicians
MS Sanatani, MD Vincent - Supportive Cancer Therapy, 2007 - Elsevier
Advances in the treatment of metastatic colorectal cancer have improved overall survival
(OS); however, this might come at the cost of increased toxicity. Health-related quality of life …
(OS); however, this might come at the cost of increased toxicity. Health-related quality of life …
Describing systemic anti-cancer therapy pathways in metastatic colorectal cancer patients using real-world data.
Background: The rapid uptake of new medicines for metastatic colorectal cancer (mCRC),
together with the wide range of potential combinations and sequences available for treating …
together with the wide range of potential combinations and sequences available for treating …
Comparative Studies of Later-Line Therapies for Metastatic Colorectal Cancer
M Obeng-Kusi - 2023 - repository.arizona.edu
Background: Advanced in the treatment landscape of metastatic colorectal cancer (mCRC)
has resulted in improved clinical outcomes for patients. Nonetheless, some patients still …
has resulted in improved clinical outcomes for patients. Nonetheless, some patients still …
Patient demographics and management landscape of metastatic colorectal cancer in the third‐line setting: Real‐world data in an australian population
ST Min, A Roohullah, A Tognela, A Jalali… - Asia‐Pacific Journal …, 2022 - Wiley Online Library
Background Colorectal cancer is the third most common cancer and second leading cause
of cancer mortality in Australia, thus carrying a significant disease burden. Aims This …
of cancer mortality in Australia, thus carrying a significant disease burden. Aims This …
Second‐line systemic therapy for metastatic colorectal cancer
S Mocellin, Z Baretta, MR i Figuls, I Sola… - Cochrane Database …, 2017 - cochranelibrary.com
Background The therapeutic management of people with metastatic colorectal cancer (CRC)
who did not respond to first‐line treatment represents a formidable challenge. Objectives To …
who did not respond to first‐line treatment represents a formidable challenge. Objectives To …